Delivering growth through partnership
I Orphan Drug Commercialisation I Medical Devices I Personal Protection Equipment (PPE)
Otago Healthcare is a company which represents both specialist biopharmaceutical companies looking to launch Orphan Drugs as well as the supply of Medical Devices and Personal Protection Equipment (PPE) in Asia, Europe and MENA.
We are a customer facing “ready to go” team with who work integrally with our partners to ensure successful product adoption and supply in these strategic markets. We have an existing footprint across Asia, Europe and MENA so can begin immediate commercialisation and supply of Medical Devices and Personal Protection Equipment through our existing suppliers around the world.READ MORE
Our team are highly skilled, industry experts who have been working in the life science sector and have a real understanding of the complexities, challenges and knowledge of launching Orphan Drugs and supplying Medical Devices and Personal Protection Equipment.
Our commitment is to make Specialist Medicines, Medical Devices and Personal Protection Equipment accessible for patients and healthcare professionals. We will continue to bring to market advances in healthcare pushing boundaries in management of rare diseases and supply of vital medical devices and PPE.
SALES & MARKETING
Our team have been instrumental in the implementation of effective sales and marketing strategies with Orphan Drugs across Europe and Middle East. We are a ready to go team which is “customer facing”, have developed large clinician, stakeholder, payer and regulatory networks.
We have significant expertise, knowledge and experience in supporting product submissions through Healthcare Technology Assessments, engaging with SMC, NICE, EUCERD and COMP for reimbursement and adoption within Europe. Otago will develop market access strategies, integrated care pathways and engage with clinical and payer customers.
Otago will work closely to support disease awareness campaigns during pre-marketing approval stage and through launch across Europe ensuring all ABPI and European regulatory sign off. Additionally, we will ensure all medical and marketing literature used across Europe is compliant with strict governmental guidelines.
PRICING & REIMBURSEMENT
We have considerable knowledge and understanding of the complex process involved in the United Kingdom and Europe for Orphan Drug pricing and reimbursement. We will work integrally with you to implement strategies for strategic markets.
Otago will support our partners discussions and marketing submissions with EMEA, Committee for Orphan Medicinal Products (COMP) and EU regulatory authorities. We will also work closely with you on drug development and regulatory strategy and compile regulatory dossiers for clinical trial approval and marketing authorization including eCTD.
We have a robust regulatory process for the supply and wholesaling of Orphan Drugs, Medical Devices and PPE to hospitals, private clinics, healthcare professionals and patient homecare. Our MHRA approved warehouse has the ability to store and distribute the product to physician, hospital, specialist clinics and organisations.
All our products are certified to international standards and specifications in Asia, Europe and MENA with full CE certification with Letters of Conformity and Declarations of Conformity. Our global suppliers and manufacturers produce PPE to international manufacturing excellence adhering to stringent CE/FDA/ISO/EN standards. We have access to both manufacturers and major companies producing PPE for global customers.